Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3988826 | Journal of Cancer Research and Practice | 2014 | 6 Pages |
Salivary gland adenocarcinoma is a rare type of head and neck cancer and often has aggressive behavior with propensity to recur and metastasize. Currently, there are no standard treatment guidelines. Surgery is however, the mainstay of treatment in resectable disease and radiation is also considered for most patients after surgery. Systemic chemotherapy is reserved for metastatic cases, but its results are often disappointing. Recent development of molecular biology has shown that salivary gland caner has several molecular changes which may guide potential therapeutic targets. Here, we report a 67 year-old man diagnosed to have metastasized minor salivary gland adenocarcinoma with diffuse human epidermal growth factor receptor-2 (HER-2)-positive, by the immunohistochemical (IHC) stain. He was treated with a trastuzumab-containing chemotherapeutic regimen with encouraging results.